S781
Clinical - Lung
ESTRO 2026
uncommon and usually transient adverse events. Our results suggest that larger PTV and greater chest wall- PTV overlap volumes may correlate with longer pain duration and earlier onset. Additional clinical risk factors should be explored in larger patient cohorts. References: Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol. 2022 Oct;23(10):e469-e478.2. UK SABR Consortium. Stereotactic Ablative Body Radiation Therapy (SABR): A Resource. Version 6.1. London: UK SABR Consortium; 2019 Jan. Available from: https://www.sabr.org.uk/wp- content/uploads/2019/04/SABRconsortium-guidelines- 2019-v6.1.0.pdf.3. Kong FM, et al. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1442-57. Keywords: Chest wall adverse events, SBRT, dose guidance 1. Andratschke N, et al. European Society for Radiotherapy and Oncology and European
Seventy-five patients with 77 lesions were enrolled for analysis. Median age was 74 years, and 59% were men. Most patients had good performance status (KPS ≥ 80 in 74.7%) but significant comorbidity (CCI ≥ 5 in 65%). Most lesions were ≤ 2 cm (85 %).Radiotherapy schedule included 48 Gy/4fx (62%) and 50-55 Gy/5fx (38%). Median PTV, PTV–rib overlap, and PTV–CW overlap were 27.5 cc (IQR 10.6–34.5), 1.04 cc (IQR 0– 1.2), and 2.91 cc (IQR 0.3–3.5), respectively. Eight (10.6%) patients developed CW side effects, all G1–2. Median time to onset was 158.5 days (range 5–443), and the median pain duration was 139.5 days (range 36–365) (Figure 1). Patients who developed CW adverse effects had significantly larger PTVs (median 39.8cc vs 18.5cc, p = 0.018) and greater PTV-rib overlap volumes (median 1.05cc vs 0.3c c, p = 0.031) (Figure 2).
Digital Poster 2102
Safety and efficacy of concurrent radiotherapy with amivantamab in patients with advanced EGFR- or MET-alterered non-small cell lung cancer Danny Lavigne 1 , Cecile Le Péchoux 1 , Angela Botticella 1 , David Planchard 2 , Benjamin Besse 2 , Pernelle Lavaud 2 ,
Anas Gazzah 2 , Nadia Guezour 3 , Stéphane Jouveshomme 3 , Jordi Remon 2 , Antonin Levy 1
1 Radiation Oncology, Gustave Roussy, Villejuif, France. 2 Medical Oncology, Gustave Roussy, Villejuif, France. 3 Pulmonology, GHPSJ, Paris, France Purpose/Objective: Amivantamab, a bispecific EGFR–MET antibody, is increasingly used in advanced non–small cell lung cancer (NSCLC) with EGFR or MET alterations. However, data on the safety and efficacy of concurrent radiotherapy remain scarce. This cohort aimed to evaluate the real-world safety and efficacy of radiotherapy delivered concurrently with amivantamab. Material/Methods: Data from patients with metastatic EGFR- or MET- altered NSCLC who received radiotherapy within 3 weeks of amivantamab administration between June 2021 and August 2025 at a single academic center were retrospectively analyzed. All radiotherapy techniques and indications were included. Acute and late radiotherapy-related toxicities (CTCAE v5.0), best clinical and radiological responses, local control (LC), post-radiotherapy progression-free survival (PFS),
In the CWAE group, larger rib and CW overlap volumes were positively correlated with longer pain duration ( ρ = 0.64 and 0.63, respectively), whereas larger PTV were linked to earlier symptom onset ( ρ = –0.60). No significant differences were observed in other clinical factors, except for gender: women experienced more chest wall pain (OR = 5.04, 95% CI: 0.94–26.9). No rib fractures were reported. Conclusion: Chest wall side effects related to SBRT for peripheral lung tumors is a clinically meaningful, though
Made with FlippingBook - Share PDF online